Compare Boston Scientific Corporation (BSX) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs ArcelorMittal SA — how do they compare? Boston Scientific Corporation trades at $42.71 (market cap $66.37B), while ArcelorMittal SA trades at $66.94 (market cap $50.59B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and ArcelorMittal SA pays a 0.9% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | MT | |
|---|---|---|
Market Cap | $66.37B | $50.59B |
Sector | Health | Basic Materials |
52-Week High | $108.14 | $71.65 |
52-Week Low | $42.63 | $30.39 |
Enterprise Value | $75.94B | $59.91B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
ArcelorMittal (MT) trades at $65.92, down 0.24% today, with a bullish technical outlook and strong recent earnings beats. The stock shows robust fundamentals with a P/E of 17.26 and P/S of 0.81, supported by a net income margin of 4.71% and consistent dividend payments. Recent news highlights expansion initiatives and a strategic AI collaboration with AWS, driving positive sentiment amid a 41% six-month gain (Zacks Investment Research, 2026-06-23).
Outlook remains positive with analyst consensus at 50% buy ratings, though risks include cyclical steel demand and high capital expenditure. The stock's valuation appears reasonable, but investors should monitor global economic conditions and steel pricing trends for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
